Practice Information:

Clinical Interest(s): Breast
Ovarian Cancer

Scientific Interest(s):

For 12 years, Dr. Dennis Slamon and his colleagues conducted clinical and laboratory research that led to the development of the breast cancer drug Herceptin. The drug targets a specific genetic alteration found in about 30 percent of breast cancer patients. In 1998, the U.S. Food and Drug Administration approved the use of the Herceptin monoclonal antibody for treatment of advanced breast cancer. Slamon's research proved a relationship between the gene HER-2/neu, which encodes a tyrosine kinase, and a particularly aggressive form of breast cancer. He continues to place research as one of his top priorities, and is currently investigating the effectiveness of Herceptin in newly diagnosed breast cancer patients. Slamon is also working to develop new treatments for women with breast and ovarian cancers.

Selected Cancer-Related Publications:

Britten CD, Kabbinavar F, Randolph Hecht J, Bello CL, Li J, Baum C, Slamon D, Hecht JR. A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period. Cancer Chemother Pharmacol. 2007.

Finn RS, Dering J, Ginther C, Wilson CA, Glaspy P, Tchekmedyian N, Slamon DJ. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro. Breast Cancer Res Treat. 2007.

Hinestrosa MC, Dickersin K, Klein P, Mayer M, Noss K, Slamon D, Sledge G, Visco FM. Shaping the future of biomarker research in breast cancer to ensure clinical relevance. Nat Rev Cancer. 2007; 7(4): 309-15.

Jones LW, Haykowsky M, Peddle CJ, Joy AA, Pituskin EN, Tkachuk LM, Courneya KS, Slamon DJ, Mackey JR. Cardiovascular risk profile of patients with HER2/neu-positive breast cancer treated with anthracycline-taxane-containing adjuvant chemotherapy and/or trastuzumab. Cancer Epidemiol Biomarkers Prev. 2007; 16(5): 1026-31.

Munster PN, Britten CD, Mita M, Gelmon K, Minton SE, Moulder S, Slamon DJ, Guo F, Letrent SP, Denis L, Tolcher AW. First study of the safety, tolerability, and pharmacokinetics of CP-724,714 in patients with advanced malignant solid HER2-expressing tumors. Clin Cancer Res. 2007; 13(4):

1238-45.

In the News:

FDA Approves New Drug that has Shown Groundbreaking Results in Patients with Estrogen-Receptor Positive Advanced Breast Cancer
New Study Finds Promising Drug Doubled Positive Effect in Hormone-Receptor Positive Breast Cancer
May is National Cancer Research Month
Promising Drug Doubled Positive Effect in Hormone-Receptor Positive Breast Cancer
VIDEO: UCLA Scientists Will Test Drug to Block Stem Cells Leading to Cancer
UCLA Scientists Taking Stem Cell Research to Cancer Patients
UCLA Cancer Researcher Cited Among Possible Winners of 2013 Nobel Prize
Breast Cancer Drug Receives Breakthrough Designation from FDA
VIDEO: High School Student Brings Chemo Bags to Cancer Patients
May is National Cancer Research Month
VIDEO: Dr. Dennis Slamon Discusses the Importance of Participating in Clinical Trials
AUDIO: Dr. Dennis Slamon and the Story of Herceptin
VIDEO: Herceptin and Chemotherapy Treatment Combo Increases Survival Rates in Early Breast Cancer Patients
Survival Significantly Increased in Early Breast Cancer after Treatment with Herceptin and Chemotherapy
Medicine is in His DNA: A Conversation with Dennis Slamon
VIDEO: Herceptin Gives Cancer Survivor Second Chance at Life
VIDEO: Dr. Dennis Slamon—Challenging "One Size Fits All" Cancer Therapies
May is National Cancer Research Month
Cancer Researcher Receives Prestigious Scheele Award
UCLA Researchers Receive $49.2 Million in Grants to Fund Research
VIDEO: Vons Donates $700,000 to Support Cancer Research
Dual Oral Combination Treatment Shows Promise for Metastatic Breast Cancer
NBC News: Breast Cancer Chemotherapy Risk
Survival Increased in Early Stage Breast Cancer After Herceptin-Chemotherapy Treatment